AXA-NK02

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAXA-NK02

Drug Alias NameAXA-NK02

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsLupus Nephritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesShanghai Jiao Tong University School of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University School of Medicine

Inactive CompaniesN/A

Active IndicationsLupus Nephritis

Inactive IndicationsN/A

Other Information

ATC CodeN/A